Granules India Limited is a leading pharmaceutical company based in Hyderabad, India. Recently, the business has gained attention for its partnership with the Greenko Group to create environmentally friendly pharmaceutical zones. As a result, many investors are now interested in learning more about Granules India’s potential, especially with regard to its share price goal.
Due to rapid expansion in its business of producing active pharmaceutical ingredients (API) for medications, Granules India announced a 7.8% increase in fourth-quarter earnings. In the three months that ended on March 31, the company’s consolidated net profit increased from 1.11 billion rupees to Rs 120 crore ($14.7 million). Although Granules’ overall costs increased by 17%, a 16% increase in its operating revenue from operations drained away at the company’s profit growth. The company’s main division, completed doses, had sales growth of 16% year over year, but its second-largest division, API, saw revenue growth of 48%. The API and ready-for-consumption medication paracetamol, which Granules solely offers in the European Union, had a 38% increase in sales. However, the United States, where the corporation receives 31% of its business, is its largest market. Methocarbamol, a prescription that relaxes muscles, is among the medications it offers in the nation; its sales increased by 60% in the most recent quarter.
In this post, we’ll examine the variables that might have an effect on Granules India’s anticipated share price between 2023 and 2030. Also, we will assess Granules India as a pharmaceutical stock and offer our professional judgment on the topic.
Continue reading to find out more about Granules India’s growth prospects and what they signify for investors!
Latest news about Granules India
➤ A 20 percent CAGR in sales and a 27 percent CAGR in EBITDA were impressive growth rates for Granules India during the previous five years. The business anticipated continuing its expansion during the next five years. High-tech, complicated formulations are anticipated to perform well for this pharmaceutical industry leader.
➤The US Food & Drug Administration (US FDA) has authorized Granules’ ANDA for Venlafaxine Hydrochloride Extended-Release Capsules, the company said.
➤The final dividend of Rs. 1.50 will have a record date of 03 August 2023, according to Granules India.
|When||Maximum Price||Minimum Price|
Granules India’s share price in 2023 is expected to experience a positive trend throughout the year. The maximum price for Granules India is predicted to be ₹392.77 around December 2023, while the minimum price is expected to be ₹222.94 in June 2023. This means that the stock is expected to grow by approximately 65% from its minimum price to its maximum price, which indicates a bullish trend in the long run.
Although the stock may experience ups and downs, it is expected to remain in an overall uptrend throughout the year. The growth percentage of the stock is significant, particularly from June 2023 to December 2023. Investors who are interested in investing in Granules India should keep a close eye on the stock’s performance and market trends.
The book value per share is increasing over the past two years, and Granules India is a company with low debt which helps the company to grow in the near future. Whereas on the other hand, MFs have recently decreased their shareholding, plus, the cash flow is declining from the core business which is a point of worry. But brokers have upgraded their target prices, which is a great opportunity. Adding to the same, the Earnings per share have also increased by more than 25% YoY to 21.34 in May 2023 and the Price-to-Book ratio has also declined from 16.3 in May 2022 to 12.95 in May 2023.
Granules India stock is expected to perform well in 2023, which makes it a potentially lucrative investment option.
|When||Maximum Price||Minimum Price|
Looking at the 2024 share price prediction table above for Granules India, we can observe a generally positive trend throughout the year. The maximum share price target in December 2024 is expected to be ₹549.89, while the minimum share price target is predicted to be ₹284.96 in May 2024. This indicates that the stock is projected to grow by approximately 93% from its minimum price to its maximum price, which presents a substantial upside potential for investors.
The average target for Granules India’s share price in 2024 is estimated to be around ₹433.77, which is encouraging news for investors searching for potentially profitable investment opportunities in the pharmaceutical industry.
Granules India stock in 2024 is expected to have a bullish outlook, with its share price expected to increase gradually over the year.
|When||Maximum Price||Minimum Price|
The maximum share price target for Granule India for January 2025 is projected to be ₹560.89, while the minimum share price target is estimated to be ₹387.07 in May 2025. This indicates that the stock is expected to grow by approximately 45% from its minimum price to its maximum price, which presents a decent return potential for investors.
While the overall outlook for Granules India in 2025 is positive, it’s important to note that the stock may still be subject to market volatility and bearish trends. Investors should exercise caution and conduct thorough research before making any investment decisions.
|Year||Maximum Price||Minimum Price|
Looking at the data for Granules India’s share price target for 2026 to 2030, it appears that there will be some fluctuations in the market. In 2026, the maximum price is expected to reach ₹466.92 and the minimum price is predicted to be around ₹326.84. This indicates a potentially bearish trend for the year.
However, in 2027, there is a possibility of a bullish trend as the maximum price is expected to be ₹396.88. From 2028 to 2030, there seems to be a significant upward trend in the share price as the maximum price is predicted to reach ₹714.39, ₹1,467.46, and ₹1,634.22 respectively.
It is important to note that the minimum price is also expected to increase gradually during these years, indicating that the growth may be steady rather than sudden.
Considering the expected growth percentage and return, it may be a good recommendation to buy Granules India’s shares in the long term.
Financial Condition of Granules India: Last 5 years
|Profit before tax||195.99||325.52||451.13||704.37||558.00|
|Price to earning||19.76||12.31||10.89||13.68||18.42|
Granules India has shown consistent growth in its revenue and profits over the last five years. From 2018 to 2022, the company’s revenue grew from ₹1,684.62 crore to ₹3,764.92 crore, marking a significant percentage growth of over 123%.
The net profit after tax (PAT) has also witnessed an upward trend during this period, growing from ₹132.59 crore in 2018 to ₹412.76 crore in 2022. The company has maintained a steady dividend payout ratio over the years, ranging between 6.76% to 19.14%.
Granules India’s operating profit margin (OPM) has fluctuated during the last five years, ranging between 16.53% to 26.43%. The company’s maximum price per share in the last five years was ₹306.50, which was recorded in March 2022, while the minimum price per share was ₹103.25 in March 2018.
Overall, Granules India has displayed consistent revenue and profit growth, with fluctuations in operating profit margin, and the company’s dividend payout ratio has remained relatively stable.
ICICI Direct is optimistic about Granules India’s prospects and has given it a buy rating with a predicted price of Rs 355.
Sharekhan is optimistic about Granules India and has given it a “buy” rating, with a predicted price of Rs 350.
It is predicted that Granules India per share price will increase to ₹392.77 by the end of 2023.
Can you provide information on Granules India’s dividend history?
Since September 18, 2003, Granules India Ltd. has announced a total of 42 dividends. Recently, the company has recommended a dividend of Rs 1.5 per share in August.
The share price target of Granules India for 2025 might be around ₹667.
The per share price of Granules India might reach around ₹1,634 by the end of 2030.
- Indigo Paints Share Price Target 2023, 2024, 2025 to 2030: Can INDIGOPNTS reach 6000 INR?
- Apollo Hospitals Enterprise Share Price Target 2023 to 2030: Can APOLLOHOSP touch 10,000 INR?
- HCL Technologies Share Price Target 2023, 2024, 2025 to 2030: Can HCLTECH reach 6000 INR?
In conclusion, Granules India has shown a significant increase in revenue and profits over the past five years. The company has seen a revenue growth of 123% from 2018 to 2022, which is an impressive achievement. Also, Granules India’s profit after tax has also increased from Rs. 132.59 crore in 2018 to Rs. 412.76 crore in 2022. However, the company has experienced a dip in operating profit in the last fiscal year, which may be a cause for concern for potential investors.
Despite this, Granules India has maintained a steady dividend payout ratio of around 10-20% over the past five years, indicating a commitment to returning value to shareholders. The stock’s Price to Earnings ratio has ranged from 10.89 to 12.95, which suggests that the stock may be slightly overvalued at present.
Overall, Granules India’s financials show positive growth trends and stable dividend payouts. However, investors should consider the recent dip in operating profit and the current valuation of the stock before making a decision to buy.
What did we learn?
- 1 Latest news about Granules India
- 2 How to buy Granules India shares?
- 3 Share Price Prediction of Granules India: 2023 to 2030
- 4 Financial Condition of Granules India: Last 5 years
- 5 Granules India share price target by Experts
- 6 FAQS
- 7 Conclusion